SecBot SecBot
SECBOTREPLAY Home › Report › VERA

VERA · Vera Therapeutics announced FDA accelerated approval for TRUTAKNA…

Vera Therapeutics, Inc. · 8-K filed Jul 7, 2026 at 12:45 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jul 7, 2026 at 12:45 ET

Vera Therapeutics announced FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. This is a transformative regulatory milestone that unlocks a commercial market for the company's lead drug candidate.

  • FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) on July 7, 2026.
  • Indication: reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.
  • No financial terms, pricing, or revenue guidance were disclosed in the filing.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access